ObsEva Files Year End 2022 Financial Statements
31 Março 2023 - 5:01PM
ObsEva Files
Year End 2022 Financial
Statements
Ad hoc announcement pursuant to Art. 53 LR of
the SIX Swiss Exchange
GENEVA, Switzerland –
March 31, 2023 –
ObsEva SA (SIX: OBSN / OTC
Pink Market:
OBSVF), a biopharmaceutical company
developing and commercializing novel therapies to improve women’s
health, today published its U.S. Annual Report on Form 10-K for
Fiscal Year 2022, including the U.S. GAAP financial results for
year-end 2022. The U.S. Annual Report on Form 10-K can be accessed
in the financial section of the Company’s website, here or directly
via the link here.
ObsEva expects to publish its Swiss Annual
Report to Shareholders, including the financial results for year
end 2022 in IFRS, in the week commencing April 24, 2023.
About ObsEvaObsEva is a
biopharmaceutical company developing novel therapies to improve
women’s reproductive health and pregnancy. ObsEva has established a
development program focused on improving in vitro fertilization
success rates. ObsEva is listed on the SIX Swiss Exchange where it
is traded under the ticker symbol “OBSN” and on the OTC Pink Market
under the ticker symbol “OBSVF”. For more information, please visit
www.ObsEva.com
For further information, please
contact:
CEO Office contactShauna
Dillonshauna.dillon@obseva.ch+41 22 552 1550
Investor ContactWill
Brownwill.brown@obseva.com +1 (334) 313-2319
###
- ObsEva - Press Release - YE22 earnings
ObsEva (NASDAQ:OBSV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
ObsEva (NASDAQ:OBSV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
